Drug transport across the blood-brain barrier

Journal of Cerebral Blood Flow and Metabolism

Volumn 32, Issue 11, 2012, Pages 1959-1972

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

blood brain barrier; cerebrospinal fluid; endothelium; receptors; vascular biology

Indexed keywords

AVIDIN; BARBITURIC ACID DERIVATIVE; BIOTIN; BRAIN DERIVED NEUROTROPHIC FACTOR I 125; CARRIER PROTEIN; CYSTEINE; CYTOCHROME P450 1A1; DIAZEPAM; FC RECEPTOR; GABAPENTIN; GLUCOSE TRANSPORTER 1; HUMAN INSULIN RECEPTOR MONOCLONAL ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN G NEUROTROPHIN FUSION PROTEIN; INSULIN RECEPTOR ANTIBODY; LAT1 PROTEIN; LEVODOPA; MELPHALAN; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1; PARAQUAT; RADIOPHARMACEUTICAL AGENT; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; BINDING AFFINITY; BIOTECHNOLOGY; BLOOD BRAIN BARRIER; BRAIN CANCER; CAPILLARY ENDOTHELIUM; CEREBROSPINAL FLUID; CHOROID PLEXUS; DIALYSATE LEVEL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TRANSPORT; GENETIC ENGINEERING; HUMAN; HYDROGEN BOND; INTRANASAL DRUG ADMINISTRATION; LIPID TRANSPORT; MOLECULAR BIOLOGY; MOLECULAR WEIGHT; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; RECEPTOR MEDIATED TRANSPORT; REVIEW; THERMODYNAMICS; TIGHT JUNCTION; TROJAN HORSE DELIVERY SYSTEM; TURNOVER TIME;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CARRIER PROTEINS; HUMANS; LIPID METABOLISM; NEUROIMAGING; PHARMACEUTICAL PREPARATIONS;

EID: 84868573143     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.126     Document Type: Review

References (130)

1. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2: 3-14. (Pubitemid 40128022)
2. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969; 40: 648-677.
3. Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 1987; 163: 319-328. (Pubitemid 17050086)
4. Mott FW. The late Professor Edwin Goldmann's investigations on the central nervous system by vital staining. Br Med J 1913; 2: 871-873.
5. Friedemann U. Blood-brain barrier. Physiol Rev 1942; 22: 125-145.
6. Broman T. The possibilities of the passage of substances from the blood to the central nervous system. Acta Psych Neurol 1941; 16: 1-16.
7. Rowland LP. Blood-brain barrier, cerebrospinal fluid, brain edema, and hydrocephalus. In: Kandel ER, Schwartz JH (eds) Principles of Neural Science. 2nd edn (Elsevier Science Publishing: New York, NY, 1985, pp 837-844.
8. Davson H. The cerebrospinal fluid. Handbook of Neurochemistry 1969; 2: 23-48.
9. Oldendorf WH. Cerebrospinal fluid formation and circulation. Prog Nucl Med 1972; 1: 336-358.
10. Cutler RW, Page L, Galicich J, Watters GV. Formation and absorption of cerebrospinal fluid in man. Brain 1968; 91: 707-720.
11. Rudick RA, Zirretta DK, Herndon RM. Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow. J Neurosci Methods 1982; 6: 253-259. (Pubitemid 13237160)
12. Yan Q, Matheson C, Sun J, Radeke MJ, Feinstein SC, Miller JA. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp Neurol 1994; 127: 23-36. (Pubitemid 24199219)
13. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975; 195: 73-83.
14. Fung LK, Shin M, Tyler B, Brem H, Saltzman WM. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res 1996; 13: 671-682. (Pubitemid 26156217)
15. Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp Neurol 1997; 145: 24-37. (Pubitemid 27244277)
16. Yamada K, Kinoshita A, Kohmura E, Sakaguchi T, Taguchi J, Kataoka K et al. Basic fibroblast growth factor prevents thalamic degeneration after cortical infarction. J Cereb Blood Flow Metab 1991; 11: 472-478.
17. Marin-Padilla M, Knopman DS. Developmental aspects of the intracerebral microvasculature and perivascular spaces: insights into brain response to latelife diseases. J Neuropathol Exp Neurol 2011; 70: 1060-1069.
18. Szentistvanyi I, Patlak CS, Ellis RA, Cserr HF. Drainage of interstitial fluid from different regions of rat brain. Am J Physiol 1984; 246: F835-F844. (Pubitemid 14075694)
19. Fishman RA, Christy NP. Fate of adrenal cortical steroids following intrathecal injection. Neurology 1965; 15: 1-6.
20. Aird RB. A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp Neurol 1984; 86: 342-358. (Pubitemid 15218169)
21. de Lange EC, Danhof M, de Boer AG, Breimer DD. Critical factors of intracerebral microdialysis as a technique to determine the pharmacokinetics of drugs in rat brain. Brain Res 1994; 666: 1-8. (Pubitemid 24359646)
22. Crawley JN, Fiske SM, Durieux C, Derrien M, Roques BP. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. J Pharmacol Exp Ther 1991; 257: 1076-1080.
23. Kristensson K, Olsson Y. Uptake of exogenous proteins in mouse olfactory cells. Acta Neuropathol 1971; 19: 145-154.
24. Merkus P, Guchelaar HJ, Bosch DA, Merkus FW. Direct access of drugs to the human brain after intranasal drug administration? Neurology 2003; 60: 1669-1671. (Pubitemid 36618097)
25. Westin U, Piras E, Jansson B, Bergstrom U, Dahlin M, Brittebo E et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005; 24: 565-573. (Pubitemid 40387270)
26. Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005; 94: 1187-1195. (Pubitemid 40904183)
27. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006; 202: 497-505. (Pubitemid 44692690)
28. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999; 1: 55-68.
29. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-249. (Pubitemid 32239479)
30. Ajay Bemis GW, Murcko MA. Designing libraries with CNS activity. J Med Chem 1999; 42: 4942-4951.
31. Cohen BE, Bangham AD. Diffusion of small non-electrolytes across liposome membranes. Nature 1972; 236: 173-174.
32. Lieb WR, Stein WD. Non-Stokesian nature of transverse diffusion within human red cell membranes. J Membr Biol 1986; 92: 111-119. (Pubitemid 16045734)
33. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23: 682-684. (Pubitemid 11237830)
34. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998; 6: 151-165. (Pubitemid 29033982)
35. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 1998; 165: 201-211. (Pubitemid 28465226)
36. Trauble H. The movement of molecules across lipid membranes: a molecular theory. J Membrane Biol 1971; 4: 193-208.
37. Hingson DJ, Diamond JM. Comparison of nonelectrolyte permeability patterns in several epithelia. J Membr Biol 1972; 10: 93-135.
38. Marrink SJ, Jahnig F, Berendsen HJ. Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations. Biophys J 1996; 71: 632-647. (Pubitemid 26289148)
39. Diamond JM, Wright EM. Molecular forces governing non-electrolyte permeation through cell membranes. Proc R Soc Lond B Biol Sci 1969; 171: 273-316.
40. Stein WD. The Molecular Basis of Diffusion Across Cell Membranes. Academic Press: New York, NY, 1967, pp 66-125.
41. Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat bloodbrain barrier. J Clin Invest 1979; 64: 145-154.
42. Chikhale EG, Ng KY, Burton PS, Borchardt RT. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res 1994; 11: 412-419. (Pubitemid 24117362)
43. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 1972; 178: 984-986.
44. Crone C. Facilitated transfer of glucose from blood into brain tissue. J Physiol 1965; 181: 103-113.
45. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol 1971; 221: 1629-1639.
46. Pardridge WM, Oldendorf WH. Transport of metabolic substrates through the blood-brain barrier. J Neurochem 1977; 28: 5-12. (Pubitemid 8022759)
47. Pardridge WM. Recent advances in blood-brain barrier transport. Annu Rev Pharmacol Toxicol 1988; 28: 25-39.
48. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011; 117: 333-345.
49. Pardridge WM, Oldendorf WH. Kinetics of blood-brain transport of hexoses. Biochim Biophys Acta 1975; 382: 377-392.
50. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chem 1990; 265: 18035-18040.
51. Pardridge WM, Oldendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta 1975; 401: 128-136.
52. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA 1999; 96: 12079-12084. (Pubitemid 29502861)
53. Stoll J, Wadhwani KC, Smith QR. Identification of the cationic amino acid transporter (System y\+) of the rat blood-brain barrier. J Neurochem 1993; 60: 1956-1959. (Pubitemid 23127608)
54. Cremer JE, Cunningham VJ, Pardridge WM, Braun LD, Oldendorf WH. Kinetics of blood-brain barrier transport of pyruvate, lactate and glucose in suckling, weanling and adult rats. J Neurochem 1979; 33: 439-445. (Pubitemid 9240930)
55. Gerhart DZ, Enerson BE, Zhdankina OY, Leino RL, Drewes LR. Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Am J Physiol 1997; 273: E207-E213.
56. Cornford EM, Oldendorf WH. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim Biophys Acta 1975; 394: 211-219.
57. Li JY, Boado RJ, Pardridge WM. Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na\+ nucleoside cotransporter CNT2. J Cereb Blood Flow Metab 2001; 21: 929-936. (Pubitemid 32729828)
58. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci 2011; 100: 3547-3559.
59. Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012; 503: 269-292.
60. Sumbria RK, Boado RJ, Pardridge WM. Brain protection from stroke with intravenous TNFa decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab 2012, in press.
61. Gjedde A, Christensen O. Estimates of Michaelis-Menten constants for the two membranes of the brain endothelium. J Cereb Blood Flow Metab 1984; 4: 241-249. (Pubitemid 14080153)
62. Schulz A, Beyhl D, Marten I, Wormit A, Neuhaus E, Poschet G et al. Proton-driven sucrose symport and antiport are provided by the vacuolar transporters SUC4 and TMT1/2. Plant J 2011; 68: 129-136.
63. Mueckler M, Caruso C, Baldwin SA, Panico M, Blench I, Morris HR et al. Sequence and structure of a human glucose transporter. Science 1985; 229: 941-945. (Pubitemid 16248486)
64. Boado RJ, Pardridge WM. Molecular cloning of the bovine blood-brain barrier glucose transporter cDNA and demonstration of phylogenetic conservation of the 50-untranslated region. Mol Cell Neurosci 1990; 1: 224-232. (Pubitemid 120038825)
65. Birnbaum MJ, Haspel HC, Rosen OM. Cloning and characterization of a cDNA encoding the rat brain glucose-transporter protein. Proc Natl Acad Sci USA 1986; 83: 5784-5788. (Pubitemid 16000596)
66. Flier JS, Mueckler M, McCall AL, Lodish HF. Distribution of glucose transporter messenger RNA transcripts in tissues of rat and man. J Clin Invest 1987; 79: 657-661. (Pubitemid 17009710)
67. Boado RJ, Pardridge WM. The brain-type glucose transporter mRNA is specifically expressed at the blood-brain barrier. Biochem Biophys Res Commun 1990; 166: 174-179. (Pubitemid 20040168)
68. Farrell CL, Pardridge WM. Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci USA 1991; 88: 5779-5783. (Pubitemid 21914829)
69. Farrell CL, Yang J, Pardridge WM. GLUT1 glucose transporter is present within apical and basolateral membranes of brain epithelial interfaces and in microvascular endothelia with and without tight junctions. J Histochem Cytochem 1992; 40: 193-199.
70. Cornford EM, Hyman S, Swartz BE. The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab 1994; 14: 106-112.
71. Dwyer KJ, Pardridge WM. Developmental modulation of blood-brain barrier and choroid plexus GLUT1 glucose transporter messenger ribonucleic acid and immunoreactive protein in rabbits. Endocrinology 1993; 132: 558-565. (Pubitemid 23056108)
72. Wang Y, Welty DF. The simultaneous estimation of the influx and efflux bloodbrain barrier permeabilities of gabapentin using a microdialysis- pharmacokinetic approach. Pharm Res 1996; 13: 398-403.
73. Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, Saito O et al. Carriermediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 2001; 906: 135-142. (Pubitemid 32595547)
74. Cornford EM, Young D, Paxton JW, Finlay GJ, Wilson WR, Pardridge WM. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res 1992; 52: 138-143.
75. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 2001; 22: 2329-2343.
76. Killian DM, Hermeling S, Chikhale PJ. Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system. Drug Deliv 2007; 14: 25-31. (Pubitemid 44764456)
77. Ghosh C, Gonzalez-Martinez J, Hossain M, Cucullo L, Fazio V, Janigro D et al. Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow. Epilepsia 2010; 51: 1408-1417.
78. Hawkins BT, Sykes DB, Rapid Miller DS. reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010; 30: 1417-1425.
79. Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA et al. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 2009; 77: 897-909.
80. Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc 2010; 58: 1749-1757.
81. Coker III GT, Studelska D, Harmon S, Burke W, O'Malley KL. Analysis of tyrosine hydroxylase and insulin transcripts in human neuroendocrine tissues. Brain Res Mol Brain Res 1990; 8: 93-98. (Pubitemid 20203936)
82. Kojima H, Fujimiya M, Matsumura K, Nakahara T, Hara M, Chan L. Extrapancreatic insulin-producing cells in multiple organs in diabetes. Proc Natl Acad Sci USA 2004; 101: 2458-2463. (Pubitemid 38269333)
83. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem 1985; 44: 1771-1778. (Pubitemid 15000282)
84. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier transferrin receptor. Metabolism 1987; 36: 892-895. (Pubitemid 17135085)
85. Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism 1988; 37: 136-140. (Pubitemid 18055228)
86. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997; 99: 14-18. (Pubitemid 27058288)
87. Duffy KR, Pardridge WM. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987; 420: 32-38. (Pubitemid 17151294)
88. Skarlatos S, Yoshikawa T, Pardridge WM. Transport of [125I]transferrin through the rat blood-brain barrier. Brain Res 1995; 683: 164-171.
89. Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 1996; 277: 1550-1559. (Pubitemid 27167171)
90. Zhang Y, Pardridge WM. Rapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem 2001; 76: 1597-1600. (Pubitemid 32198265)
91. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001; 114: 168-172. (Pubitemid 32184738)
92. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002; 81: 203-206. (Pubitemid 34808868)
93. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 1990; 54: 1882-1888.
94. Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis 2008; 30: 94-102.
95. Karkan D, Pfeifer C, Vitalis TZ, Arthur G, Ujiie M, Chen Q et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One 2008; 3: e2469.
96. Che C, Yang G, Thiot C, Lacoste MC, Currie JC, Demeule M et al. New Angiopepmodified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem 2010; 53: 2814-2824.
97. Zhou QH, Boado RJ, Lu JZ, Hui EK-W, Pardridge WM. Monoclonal antibody-glialderived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab Dispos 2010; 38: 566-572.
98. Roberts RL, Fine RE, Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 1993; 104(Pt 2): 521-532. (Pubitemid 23098690)
99. Vorbrodt AW. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J Neurocytol 1989; 18: 359-368. (Pubitemid 19147403)
100. Huwyler J, Pardridge WM. Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem 1998; 70: 883-886. (Pubitemid 28079381)
101. Bickel U, Kang YS, Yoshikawa T, Pardridge WM. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem 1994; 42: 1493-1497. (Pubitemid 24338023)
102. Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 1995; 12: 807-816.
103. Boado RJ, Zhang YF, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 2007; 96: 381-391. (Pubitemid 46232272)
104. Boado RJ, Zhang Y, Wang Y, Pardridge WM. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng 2009; 102: 1251-1258.
105. Boado RJ, Zhang YF, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem 2007; 18: 447-455. (Pubitemid 46493516)
106. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther 2000; 292: 1048-1052. (Pubitemid 30136600)
107. Boado RJ, Hui EK, Lu JZ, Pardridge WM. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther 2010; 333: 961-969.
108. Boado RJ, Pardridge WM. Comparison of blood-brain barrier transport of glialderived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos 2009; 37: 2299-2304.
109. Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol 2010; 146: 84-91.
110. Greenblatt DJ, Sethy VH. Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorezepam, and oxazepam. Psychopharmacology (Berl) 1990; 102: 373-378. (Pubitemid 20335065)
111. Christian BT, Vandehey NT, Fox AS, Murali D, Oakes TR. Converse AK, et al. The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging. Neuroimage 2009; 44: 1334-1344.
112. Boado RJ, Zhang Y, Xia CF, Wang Y, Pardridge WM. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem 2008; 19: 731-739. (Pubitemid 351431405)
113. Zhou QH, Lu JZ, Hui EK, Boado RJ, Pardridge WM. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug Chem 2011; 22: 1611-1618.
114. Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC et al. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 1992; 89: 5462-5466.
115. Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 1997; 100: 1804-1812. (Pubitemid 27431339)
116. Ono M, Cheng Y, Kimura H, Cui M, Kagawa S, Nishi R et al. Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of beta-amyloid plaques in Alzheimer's brains. J Med Chem 2011; 54: 2971-2979.
117. Sumbria RK, Boado RJ, Pardridge WM. Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Abeta peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein. Bioconjug Chem 2012; 23: 1318-1321.
118. Kurihara A, Pardridge WM. Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjug Chem 2000; 11: 380-386. (Pubitemid 30324904)
119. Kurihara A, Pardridge WM. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Canc Res 1999; 54: 6159-6163. (Pubitemid 30035637)
120. Kurihara A, Deguchi Y, Pardridge WM. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem 1999; 10: 502-511. (Pubitemid 29243335)
121. Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide ('peptide') nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA 1995; 92: 5592-5596.
122. Knudsen H, Nielsen PE. Antisense properties of duplex-and triplex-forming PNAs. Nucleic Acids Res 1996; 24: 494-500. (Pubitemid 26088514)
123. Suzuki T, Wu D, Schlachetzki F, Li JY, Boado RJ, Pardridge WM. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med 2004; 45: 1766-1775. (Pubitemid 47618489)
124. Pardridge WM. Misconceptions about the blood-brain barrier. In: Pardridge WM moderator. Blood-brain barrier: interface between internal medicine and brain Ann Int Med, 1986; 105: 82-95.
125. Bar T. The vascular system of the cerebral cortex. Adv Anat Embryol Cell Biol 1980; 59: I-VI, 1-62.
126. Duvernoy H, Delon S, Vannson JL. The vascularization of the human cerebellar cortex. Brain Res Bull 1983; 11: 419-480. (Pubitemid 14249237)
127. Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target 2010; 18: 157-167.
128. Pardridge WM, Boado RJ. Molecular cloning and regulation of gene expression of blood-brain barrier glucose transporter. In: Pardridge WM (ed The Blood-Brain Barrier: Cellular and Molecular Biology. Raven Press: New York, 1993, pp 347-362.
129. Sarko D, Beijer B, Garcia Boy R, Nothelfer EM, Leotta K, Eisenhut M et al. The pharmacokinetics of cell-penetrating peptides. Mol Pharm 2010; 7: 2224-2231.
130. Boado RJ, Zhang Y, Xia CF, Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human bloodbrain barrier. Biotechnol Bioeng 2008; 99: 475-484. (Pubitemid 351158294)